Apremilast in Psoriatic Arthritis in Real-life Clinical Practice in Greece
- Conditions
- Psoriatic Arthritis
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Genesis Pharma S.A.
- Target Recruit Count
- 170
- Registration Number
- NCT03780504
- Locations
- 🇬🇷
Euromedica Private Clinic, ThessalonÃki, Greece
Retrospective and Prospective Study of POmalidomide Plus LoW Dose Dexa Efficacy in RRMM Patients Under Real-Life Conditions
Completed
- Conditions
- Relapse/Refractory Multiple Myeloma
- First Posted Date
- 2017-11-27
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- Genesis Pharma S.A.
- Target Recruit Count
- 110
- Registration Number
- NCT03353545
- Locations
- 🇬🇷
Ag.Andreas General Hospital, Patra, Greece
A Study of Treatment With APRemilast in Moderate psoriAsIS in Real Life clinicAL Practice (The 'APRAISAL' Study)
Completed
- Conditions
- Moderate Plaque Psoriasis
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Genesis Pharma S.A.
- Target Recruit Count
- 302
- Registration Number
- NCT03059953
- Locations
- 🇬🇷
401 General Military Hospital, Athens, Greece
Real-world Evidence Prospective Study on the Effect of Nab-paclitaxel Treatment on the Clinical Outcomes and HRQoL in Patients With MBC in Greece
Completed
- Conditions
- Metastatic Breast Cancer
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- Genesis Pharma S.A.
- Target Recruit Count
- 156
- Registration Number
- NCT02626013
- Locations
- 🇬🇷
Athens, Athens, Greece
A Multicenter, Prospective, oBservational Study to assEss the Clinical activitY and Impact on symptOm Burden and patieNts' HRQoL of Treatment With trabecteDin in aSTS in a Real World Setting in Greece
Completed
- Conditions
- Advanced Soft Tissue Sarcoma
- First Posted Date
- 2015-12-01
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- Genesis Pharma S.A.
- Target Recruit Count
- 63
- Registration Number
- NCT02618122
- Locations
- 🇬🇷
Thessaloniki, Thessaloniki, Greece
A Retrospective Chart Review Study of the Outcomes of 2nd Line Therapy With LEn/Dex in Greek Patients With R/R Multiple MyEloma and the Treatment PatterNs Following Progressive Disease
Completed
- Conditions
- Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2018-05-22
- Lead Sponsor
- Genesis Pharma S.A.
- Target Recruit Count
- 207
- Registration Number
- NCT02608515
- Locations
- 🇬🇷
Patra, Patra, Greece
© Copyright 2025. All Rights Reserved by MedPath